Mirum Pharmaceuticals (MIRM) PT Lowered to $132 at Citizens: Has Strong Momentum
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Mirum Pharmaceuticals (MIRM) Defended by Second Outlet, This time from Evercore: 'we think the move down is noise in a volatile tape this morning.'
February 26, 2026 10:50 AM ESTEvercore ISI analyst Gavin Clark-Gartner reiterated an Outperform rating and $101.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).
The analyst comments "Am writing this on a plane so apologies if theres a lag. Getting at ton of questions on why stock is down ~15%. We dont... More
